• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Healthcare

SHS nears EUR 250m hard cap on sixth fund

  • Rachel Lewis
  • 21 July 2022
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

SHS Gesellschaft, a German specialist healthcare investor, has held a EUR 220m first close on its sixth fund, just EUR 30m shy of the fund’s hard cap.

SHS VI has already exceeded its EUR 200m target and has a hard cap of EUR 250m, which it hopes to reach in the coming weeks with commitments from LPs already underway, the GP’s managing partner Uwe Steinbacher told Unquote.

The fund’s predecessor, SHS V, closed at EUR 130m in July 2019, short of its EUR 150m target, and is near full deployment, said Steinbacher. 

SHS VI

  • Target:

    EUR 200m

  • Focus:

    Healthcare

  • Fund manager:

    SHS

The raise comes at a time of heightened interest in healthcare GPs, in what is set to be a record year for specialist fundraising. “We have done investments with other private equity funds,” said Steinbacher. “We bring expertise and insight into the healthcare system for many funds who are quite agnostic.”

Recent deals of joint equity tickets include its expansion investment into Norweigan digital health platform Dr.Dropin, alongside Yabeo Capital.

Investors

SHS VI already has around 60 investors with more than half of those participating in the firm’s predecessor funds. They include funds-of-funds, insurance companies, pension funds, foundations, family offices, banks, healthcare groups, church investors and entrepreneurs.

Among the fund’s largest investors are the European Investment Fund, Scandinavian foundation Realdania, Switzerland’s Helsana HealthInvest, L-Bank Baden-Württemberg and larger family offices. SHS also said it has also made a significant investment in the vehicle.

Investments

Like its predecessor, Fund VI will aim to make around 12-15 investments across its 10+2 life span and will make both buyout and growth capital investments. It targets companies that are profitable or with a clear path to profitability, but not those that are pre-revenue.

The average ticket size will be EUR 15m up to a maximum of EUR 50m, said Steinbacher. If the investment requires far more than 20% of the fund, the GP will seek co-investment from its LPs.

The fund will invest across different healthcare subsectors, including medical devices, diagnostics, digital health, healthcare services, and life sciences. It will not, however, finance early-stage drug development companies because the time they take to come to market is often longer than the lifetime of the fund.

The fund is focused on making investments in expansion and innovation financing, succession situations and shareholder changes.

SHS invests across Europe with an emphasis on DACH, Benelux and the Nordics.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Healthcare
  • Buyout
  • GPs
  • healthcare
  • SHS Gesellschaft für Beteiligungsmanagement

More on Healthcare

Bolt-ons and buy-and-build platforms
The Bolt-Ons Digest – 26 January 2023

Unquote’s selection of the latest add-ons, with ICG's Circet, Five Arrows' Mintec, Carlyle's Jagex, and more

  • Expansion
  • 26 January 2023
German healthcare
German health minister’s 'locust sponsors' comments spook live healthcare deals

New entrants scared by remarks on limiting profits; existing investors expected to rush to complete bolt-ons

  • Buyouts
  • 25 January 2023
Biotech drug discovery companies
IK readies Swedish biotech group Mabtech for exit

Jefferies hired as sellside advisor; dual-track process for potential sale or IPO considered

  • Exits
  • 23 January 2023
Fundraising in euros
EQT on track for 2023 final close for Fund X

GP has so far raised more than EUR 16bn for the vehicle against EUR 20bn target

  • Buyout
  • 18 January 2023

Latest News

B2B software companies
  • Exits
Main Capital exits Onventis in SBO to Keensight

Exit from Main Fund V comes three years after the GP acquired the Germany-based procurement technology company

  • 26 January 2023
Bolt-ons and buy-and-build platforms
  • Expansion
The Bolt-Ons Digest – 26 January 2023

Unquote’s selection of the latest add-ons, with ICG's Circet, Five Arrows' Mintec, Carlyle's Jagex, and more

  • 26 January 2023
Lucie Cawood of Travers Smith
  • Advisory
Travers Smith names new head of PE and financial sponsors group

Lucie Cawood's appointment follows poaching of Ian Shawyer by Cleary Gottlieb earlier this month

  • 25 January 2023
German healthcare
  • Buyouts
German health minister’s 'locust sponsors' comments spook live healthcare deals

New entrants scared by remarks on limiting profits; existing investors expected to rush to complete bolt-ons

  • 25 January 2023
Back to Top

Most read

B2B software companies
Main Capital exits Onventis in SBO to Keensight
Bolt-ons and buy-and-build platforms
The Bolt-Ons Digest – 26 January 2023
Lucie Cawood of Travers Smith
Travers Smith names new head of PE and financial sponsors group
German healthcare
German health minister’s 'locust sponsors' comments spook live healthcare deals
The Statue of Liberty in New York
Ardian plans North American drive with tech, services deals on radar
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013